IOL Chemicals and Pharmaceuticals Limited (IOLCP) fundamentals
IOL Chemicals and Pharmaceuticals Limited is a listed company in Pharmaceuticals & Biotechnology, part of the Healthcare sector, listed on the NSE as IOLCP (ISIN INE485C01029). This page carries its reported financials, balance sheet, cash flow, shareholding pattern and valuation ratios.
What IOL Chemicals and Pharmaceuticals Limited does
IOL Chemicals and Pharmaceuticals Limited is engaged in manufacturing and selling of pharmaceutical and chemical products. The Company operates through two segments: Chemical and Pharmaceutical. The Chemical segment produces and sells Ethyl Acetate, Iso Butyl Benzene, Acetyl Chloride, Mono Chloro Acetic Acid, Para Amino Phenol (PAP), and others. The Pharmaceutical segment produces and sells various active pharma ingredients (API) including Ibuprofen, Metformin, Fenofibrate, Lamotrigine, Clopidogrel Bisulphate, Pantoprazole, Gabapentin, Paracetamol, and others. Its API product portfolio includes Pantoprazole Sodium, Clopidogrel Bisulphate (Form II), Losartan Potassium, Levetiracetam, and Fenofibrate (Micronised). Its Specialty Chemical division includes Ethyl Acetate, Iso Butyl Benzene, Mono Chloro acetic Acid, and Acetic Anhydride. Its Ethyl Acetate is used in industries like flexible packaging, pharmaceuticals, ink, food processing, pesticides, and the paint industry.
Valuation and market data
| Last close | ₹211.43 |
|---|---|
| Market capitalisation | ₹6,205 crore |
| Enterprise value | ₹6,238 crore |
| P/E (TTM) | 45.08 |
| Price to book | 3.45 |
| Price to sales (TTM) | 1.46 |
| Book value per share | ₹61.28 |
| Dividend yield | 47.30% |
| Sector | Healthcare |
| Industry | Pharmaceuticals & Biotechnology |
| Listed since | Mon Nov 08 |
Annual results
| Period | Revenue | Profit before tax | Net profit | EPS |
|---|---|---|---|---|
| Mar 2026 | ₹2,340 crore | ₹184 crore | ₹138 crore | 4.69 |
| Mar 2025 | ₹2,102 crore | ₹138 crore | ₹101 crore | 3.44 |
| Mar 2024 | ₹2,163 crore | ₹183 crore | ₹135 crore | 4.61 |
| Mar 2023 | ₹2,243 crore | ₹189 crore | ₹140 crore | 23.84 |
| Mar 2022 | ₹2,216 crore | ₹223 crore | ₹166 crore | 28.22 |
Figures are as reported (standalone), in ₹ crore.
Shareholding pattern
As of Jun 2026:
| Promoters | 62.3% |
|---|---|
| Foreign institutions (FII) | 4.9% |
| Mutual funds | 0.0% |
| Other domestic institutions | 0.4% |
| Retail and others | 32.4% |
More on BreakPoint
FundaX company research covers every listed company with reported financials. BreakPoint Pro adds the BreakPoint iQ score, the screener and the multibagger board.
Data is sourced from exchange filings and vendor feeds and is for research, not investment advice. Figures can be restated by the company after publication.